MAPK10 and chronic myelogenous leukemia, BCR-ABL1 positive: Most noteworthy, as they have not been identified in CML cell lines [24,26-28], were PDGFRB (P<6.2E-6), ILK (P<6.2E-6), and TESK1 (P<0.035) as specific targets of dasatinib, and CHEK2 (P<0.0012), MAP2K1 (P<6.2E-6), and MAP2K2 (P<6.2E-6) specific for bosutinib, CDK9 (nilotinib, P<0.0093) and MAPK8, MAPK9 and MAPK10 (bafetinib and nilotinib, all 3 P<2.59E-5).